Roche Pharmaceuticals A/S
CVR number: 25230515
Flaskehalsen 17, 1799 København V
tel: 36399900
Income statement (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 718.24 | 701.85 | 732.83 | 785.58 | 761.42 |
| Other operating income | 139.94 | 120.97 | 119.93 | ||
| Costs of manufacturing | - 599.82 | - 636.50 | - 616.28 | ||
| Gross profit | 126.12 | 126.86 | 133.01 | 149.09 | 145.14 |
| Costs of management | -24.35 | -36.02 | -31.91 | ||
| Costs of distribution | -87.79 | -87.87 | -88.92 | ||
| Other operating expenses | - 138.47 | - 110.62 | - 101.36 | ||
| EBIT | 22.45 | 10.98 | 22.34 | 35.53 | 42.88 |
| Other financial income | 0.01 | 0.41 | 1.47 | ||
| Other financial expenses | -0.05 | -0.17 | -0.50 | ||
| Pre-tax profit | 21.75 | 12.30 | 22.31 | 35.78 | 43.85 |
| Income taxes | -6.05 | -16.22 | -7.31 | ||
| Net earnings | 21.75 | 12.30 | 16.25 | 19.56 | 36.54 |
Assets (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Buildings | 6.98 | 8.31 | |||
| Machinery and equipment | 0.22 | 7.17 | 7.42 | ||
| Tangible assets total | 0.22 | 14.15 | 15.73 | ||
| Other receivables | 351.75 | 378.44 | |||
| Investments total | 351.75 | 378.44 | |||
| Long term receivables total | |||||
| Finished products/goods | 173.38 | 137.66 | 154.07 | ||
| Inventories total | 173.38 | 137.66 | 154.07 | ||
| Current trade debtors | 119.63 | 95.79 | 157.75 | ||
| Current amounts owed by group member comp. | 54.85 | 130.21 | 23.45 | ||
| Prepayments and accrued income | 2.02 | 0.12 | 1.86 | ||
| Current other receivables | 2.91 | 3.97 | 4.49 | ||
| Current deferred tax assets | 1.47 | 7.77 | 0.28 | ||
| Short term receivables total | 180.87 | 237.86 | 187.84 | ||
| Balance sheet total (assets) | 351.75 | 378.44 | 354.47 | 389.68 | 357.64 |
Equity and liabilities (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 159.93 | 127.23 | 4.00 | 4.00 | 4.00 |
| Shares repurchased | 60.00 | ||||
| Retained earnings | -21.75 | -12.30 | 123.23 | 79.49 | 99.05 |
| Profit of the financial year | 21.75 | 12.30 | 16.25 | 19.56 | 36.54 |
| Shareholders equity total | 159.93 | 127.23 | 143.49 | 163.05 | 139.58 |
| Provisions | 2.99 | 8.82 | 1.58 | ||
| Non-current other liabilities | 0.70 | ||||
| Non-current liabilities total | 0.70 | ||||
| Current trade creditors | 16.11 | 15.34 | 11.91 | ||
| Current owed to group member | 125.69 | 135.21 | 126.66 | ||
| Short-term deferred tax liabilities | 2.94 | ||||
| Other non-interest bearing current liabilities | 66.21 | 67.25 | 74.97 | ||
| Current liabilities total | 208.00 | 217.81 | 216.48 | ||
| Balance sheet total (liabilities) | 159.93 | 127.23 | 355.17 | 389.68 | 357.64 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.